文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

心脏骤停后磷脂筛查发现血浆溶血磷脂酰胆碱降低:补充治疗作为新治疗途径

Phospholipid Screening Postcardiac Arrest Detects Decreased Plasma Lysophosphatidylcholine: Supplementation as a New Therapeutic Approach.
PubMed 文献 · Crit Care Med · 2022-01-01
一句话结论心脏骤停后血浆溶血磷脂酰胆碱降低与不良预后相关,动物实验中补充特定溶血磷脂酰胆碱种类可提高生存率并改善脑功能。

本研究为临床病例对照研究加转化实验室研究,先对成人心脏骤停患者和对照者血浆进行磷脂筛查,质谱分析加多变量回归发现血浆溶血磷脂酰胆碱水平是心脏骤停的独立判别指标,且其降低与患者不良预后相关。大鼠模型中也观察到类似关联,心脏骤停时间越长,血浆溶血磷脂酰胆碱耗竭越显著。在10分钟窒息性心脏骤停大鼠模型中,补充溶血磷脂酰胆碱(18:1)和(22:6)显著提高生存率并改善存活大鼠脑功能,而补充未在心脏骤停后下降的溶血磷脂酰胆碱(18:0)则无获益。

要点

  • 成人心脏骤停患者血浆溶血磷脂酰胆碱水平降低,且是心脏骤停的独立判别指标。
  • 血浆溶血磷脂酰胆碱降低与心脏骤停患者不良预后相关。
  • 大鼠模型中,心脏骤停时间越长,血浆溶血磷脂酰胆碱耗竭越显著,提示与损伤严重程度相关。
  • 10分钟窒息性心脏骤停大鼠中,补充溶血磷脂酰胆碱(18:1)和(22:6)较对照显著提高生存率并改善存活大鼠脑功能。
  • 补充溶血磷脂酰胆碱(18:0)(10分钟心脏骤停后血浆未下降的种类)无获益。

适用人群与场景

  • 成人心脏骤停患者(临床病例对照部分)及雄性Sprague-Dawley大鼠(转化实验室部分)。
  • 原文未提及具体的纳入/排除标准、急诊/ICU/院前场景或病情阶段。

诊断标准与关键阈值

  • 原文未提及具体的诊断标准、评分界值或启动/停止阈值;仅报告血浆溶血磷脂酰胆碱水平经质谱分析加多变量回归分析为心脏骤停的独立判别指标。

处置流程与药物剂量

  • 原文未提及人体给药方案;动物实验中,10分钟窒息性心脏骤停复苏后大鼠随机接受溶血磷脂酰胆碱种类或赋形剂治疗,补充溶血磷脂酰胆碱(18:1)和(22:6)显著提高生存率并改善存活大鼠脑功能,补充溶血磷脂酰胆碱(18:0)无获益;具体剂量、途径、频次原文未提及。

红旗征与不能漏的情况

  • 原文未提及需要立刻处理或不能漏诊的红旗征。

研究设计与关键结果

  • 研究类型为临床病例对照研究加转化实验室研究;人群为成人心脏骤停患者和雄性Sprague-Dawley大鼠;干预为复苏后大鼠随机接受溶血磷脂酰胆碱种类或赋形剂治疗。
  • 质谱分析加多变量回归发现血浆溶血磷脂酰胆碱水平是心脏骤停的独立判别指标,其降低与患者不良预后相关。
  • 大鼠模型中,心脏骤停时间越长,血浆溶血磷脂酰胆碱耗竭越显著。
  • 10分钟心脏骤停大鼠中,补充溶血磷脂酰胆碱(18:1)和(22:6)较对照显著提高生存率,存活大鼠脑功能显著改善;补充溶血磷脂酰胆碱(18:0)无获益。

证据类型、等级与局限

  • 证据类型为临床病例对照研究加转化实验室研究(动物实验);原文未提及证据等级或推荐强度;局限性包括原文未报告样本量、单中心(研究机构)、动物模型结果需前瞻性验证。

对床旁实践的改变

  • 原文提示血浆溶血磷脂酰胆碱降低与心脏骤停后不良预后相关,补充特定溶血磷脂酰胆碱种类(18:1和22:6)在动物模型中提高生存率并改善脑功能,但尚不能改变急诊/ICU床旁实践;适用人群、不适用人群及常见陷阱原文未提及。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: Cardiac arrest and subsequent resuscitation have been shown to deplete plasma phospholipids. This depletion of phospholipids in circulating plasma may contribute to organ damage postresuscitation. Our aim was to identify the diminishment of essential phospholipids in postresuscitation plasma and develop a novel therapeutic approach of supplementing these depleted phospholipids that are required to prevent organ dysfunction postcardiac arrest, which may lead to improved survival.

DESIGN: Clinical case control study followed by translational laboratory study.

SETTING: Research institution.

PATIENTS/SUBJECTS: Adult cardiac arrest patients and male Sprague-Dawley rats.

INTERVENTIONS: Resuscitated rats after 10-minute asphyxial cardiac arrest were randomized to be treated with lysophosphatidylcholine specie or vehicle.

MEASUREMENTS AND MAIN RESULTS: We first performed a phospholipid survey on human cardiac arrest and control plasma. Using mass spectrometry analysis followed by multivariable regression analyses, we found that plasma lysophosphatidylcholine levels were an independent discriminator of cardiac arrest. We also found that decreased plasma lysophosphatidylcholine was associated with poor patient outcomes. A similar association was observed in our rat model, with significantly greater depletion of plasma lysophosphatidylcholine with increased cardiac arrest time, suggesting an association of lysophosphatidylcholine levels with injury severity. Using a 10-minute cardiac arrest rat model, we tested supplementation of depleted lysophosphatidylcholine species, lysophosphatidylcholine(18:1), and lysophosphatidylcholine(22:6), which resulted in significantly increased survival compared with control. Furthermore, the survived rats treated with these lysophosphatidylcholine species exhibited significantly improved brain function. However, supplementing lysophosphatidylcholine(18:0), which did not decrease in the plasma after 10-minute cardiac arrest, had no beneficial effect.

CONCLUSIONS: Our data suggest that decreased plasma lysophosphatidylcholine is a major contributor to mortality and brain damage postcardiac arrest, and its supplementation may be a novel therapeutic approach.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Nishikimi M, Yagi T, Shoaib M, et al. Phospholipid Screening Postcardiac Arrest Detects Decreased Plasma Lysophosphatidylcholine: Supplementation as a New Therapeutic Approach. Crit Care Med. 2022. PMID: 34259447. doi:10.1097/CCM.0000000000005180

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。